enzh-TWfrdeitjaptrues
You are here: Home Publications Pub-2014 Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia

Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia


Can't see this document? Click Here

Legal | Privacy

Copyright © Bing Center for Waldenstrom's Macroglobulinemia 2000 - 2021